AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04233255 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Seum CPK, CK-MM levels, Lactate dehydrogenase and alanine aminotransferase.
Description: measured in U/L using ELISA.
Study NCT00594009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venovenous CO2 Removal (VVCO2R) in COPD
Description: Patients who meet criteria will be placed on an extracorporeal circuit consisting of an oxygenator, centrifugal pump, tubing and indwelling double lumen venous catheter for CO2 removal for up to 96 hours for treatment of COPD exacerbation requiring hospitalization and intensive care
Study NCT01573988 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Increasing eating frequency
Description: The subjects receive the same breakfast with two sequences :~* breakfast in one intake at 8:00~* breakfast in four isocaloric intakes (8:00, 9:00, 10:00, 11:00) The sequence made twice : one for metabolic study and one for the study of eating behavior~The lunch during metabolic study is a standard meal The lunch during behavioural study is an ad libitum buffet test meal.~The administration order is determined by randomized allocation. The wash-out period is one to three weeks.~There are not diet or exercise interventions.
Study NCT02946515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: The educational intervention will be the online simulation training program. Participants will be taught how to use the simulation during a 30 minute orientation session with a research staff person. We will use a mastery based approach rather than prescribing an absolute number of hours participants need to play. The criteria are as follows: 1) achieving a score of 90% or more on 2 out of the last 3 simulations played or 2) maximum of 8 hours of play, whichever comes first. After the orientation sessions, training sessions will be completed by participants on their own. The research team will confirm remote usage, and contact participants by email and phone to prompt usage as needed. The research team anticipates that the proposed method will accommodate for participant schedules while still ensuring intervention compliance.
Study NCT02946515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wait List Control
Description: Access to the online simulation training after the follow-up measurement visit is complete
Study NCT01315158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Alone
Description: Recommended Propofol doses before considering crossover:~* Induction: 2-2.5 mg/kg~* Maintenance: 0.1-0.2 mg/kg/min
Study NCT01315158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol+Benzo/Opioids
Description: 1. Recommended Versed:~   a. Prior to intubation~  * patient is \< 50 kg = 1 mg Versed~  * patient is 50-75 kg = 1.5 mg Versed~  * patient is > 75 kg = 2 mg Versed~2. Recommended Fentanyl~   1. Prior to intubation = 0.5 ug/kg~  2. Total procedural dose = 1 ug/kg
Study NCT02561689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fissure sealing
Description: Procedure:~* The included teeth of the participating patients will in any case be sealed, but in this study, the operator is not free to choose the material, the material choice is determined by randomisation~* Standardized radiographs (bitewings) will be taken before treatment and after 1, 2, 3 years and possibly after 5 years. Baseline radiograph can be taken up to six months before treatment. If using conventional radiography, double-film packs will be used. A maximum of 8/10 bitewings will be taken during the study period of 3/5 years~* The occlusal surface is sealed by the dentist or dental hygienist.~* Clinical evaluation of the quality of sealants and the need for re-treatments during the follow-up will be performed after 1, 2 and 3 years and possibly after 5 years
Study NCT02547064 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glidescope guided intubation
Study NCT02547064 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope guided intubation
Study NCT02547064 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope®
Study NCT02547064 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GlideScope®
Study NCT03169127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Description: After lower third molars surgeries, pharmacogenetic and clinical efficacy of Ibuprofen 600mg was study.
Study NCT00028496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox-CEA(6D)/TRICOM vaccine
Description: Given intradermally
Study NCT00028496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given subcutaneously
Study NCT00028496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox GM-CSF vaccine adjuvant
Description: Given intradermally
Study NCT00976989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840 mg loading dose intravenously (IV), then 420 mg IV 3-weekly.
Study NCT00976989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg loading dose IV, then 6 mg/kg every 3 weeks.
Study NCT00976989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEC
Description: 5-fluorouracil 500 mg/m\^2, epirubicin 100 mg/m\^2 and cyclophosphamide 600 mg/m\^2.
Study NCT00976989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m\^2 for the first dose; 100 mg/m\^2 if no dose limiting toxicity occurs.
Study NCT00976989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCH
Description: Trastuzumab followed by carboplatin at target area under the plasma concentration-time curve (AUC) 6 and docetaxel at a starting dose of 75 mg/m\^2. All treatments were given every three weeks by the IV route.
Study NCT02491333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: true acupuncture
Description: True acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.
Study NCT02491333 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sham acupuncture
Description: Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.
Study NCT02491333 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.
Study NCT02491333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Metformin will be given at 0.5g/times, 3 times one day and for 4 month.
Study NCT02491333 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo metformin
Description: Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month.
Study NCT02491333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo metformin
Description: Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month.
Study NCT01488695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope Groove
Description: GlideScope Groove
Study NCT01488695 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control: Macintosh blade
Description: Control: Patients will be intubated using the Macintosh blade
Study NCT04217941 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Health education with practical demonstration of nasal ointment
Description: Health education with practical demonstration of medicine was compared to health education without practical demonstration
Study NCT04217941 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Health education with practical demonstration of nasal ointment
Description: Health education with practical demonstration of medicine was compared to health education without practical demonstration
Study NCT02478099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPDL3280A
Description: Anti-PD-L1 antibody
Study NCT03852719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bulevirtide
Description: Administered via SC injections
Study NCT04104776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-0209
Description: CPI-0209 alone
Study NCT03308708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion
Description: Norepinephrine infusion (5miclml) is immediately started after spinal anesthesia. Rate starts at 30 ml/h and modified according to hemodynamic state
Study NCT00346788 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical approach for total knee arthroplasty
Description: total knee arthroplasty surgery using minimally invasive surgery or standard technique.
Study NCT00346788 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical approach for total knee arthroplasty
Description: total knee arthroplasty surgery using minimally invasive surgery or standard technique.
Study NCT02732548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Study NCT02732548 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Negative Pressure Wound Therapy (NPWT)
Study NCT02732548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIRODERM Application(s)
Study NCT02732548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: wound measurement, debridement, photography of wound, moist wound environment, infection management, nutritional support
Study NCT02732548 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: wound measurement, debridement, photography of wound, moist wound environment, infection management, nutritional support
Study NCT00834262 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study NCT00834262 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 50
Description: Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study NCT00834262 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 70
Description: Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study NCT02595619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RRT plus ECCO2R
Description: Patients with acute kidney injury will be treated with Renal replacement therapy associated to extracorporeal carbon dioxide removal in a single treatment
Study NCT01158781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: gait, balance, arm function, cognition
Description: 12 weeks of training for balance, gait, upper limb function, and cognition, including functional electrical stimulation with surface electrodes, robotics, and motor learning
Study NCT03779698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BiodentineTM
Description: In the experimental group, BiodentineTM was used following the manufacturer's recommendations. The whole pulp chamber was entirely filled with BiodentineTM until the occlusal surface. Follow-up was done for all children clinically at 3, 6 and 12 months and radiographically at 6 and 12 months.
Study NCT03779698 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BiodentineTM
Description: In the experimental group, BiodentineTM was used following the manufacturer's recommendations. The whole pulp chamber was entirely filled with BiodentineTM until the occlusal surface. Follow-up was done for all children clinically at 3, 6 and 12 months and radiographically at 6 and 12 months.
Study NCT03779698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formocresol
Description: In control group, a sterile cotton pellet moistened with 1:5 concentration formocresol then blotted to remove excess was placed for 5 minutes on the pulp stumps and then the pulps were covered with zinc oxide-eugenol (IRM; Dentsply, Milford, DE) dressing. Follow-up was done for all children clinically at 3, 6 and 12 months and radiographically at 6 and 12 months.
Study NCT03779698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formocresol
Description: In control group, a sterile cotton pellet moistened with 1:5 concentration formocresol then blotted to remove excess was placed for 5 minutes on the pulp stumps and then the pulps were covered with zinc oxide-eugenol (IRM; Dentsply, Milford, DE) dressing. Follow-up was done for all children clinically at 3, 6 and 12 months and radiographically at 6 and 12 months.
Study NCT04661982 — intervention group
Intervention type: OTHER
Intervention: Long-term Follow-up
Description: Undergo long term follow-up
Study NCT04661982 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04661982 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01190501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: complier device
Description: The procedure of use of complier has to follow the recommendations for standardization of subject conditions.~Assessment of arterial distensibility: pulse wave velocity (PWV), aortic stiffness is assessed by PWV which is a classic index of arterial stiffness. A semi-automatic device is used to measure carotid-femoral PWV. The distance covered by the pulse wave is measured on the surface of the body and represented the distance between the 2 recording sites.
Study NCT02094651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: divalproex sodium
Description: The drug is an FDA approved medication for seizures but has not been approved for the treatment of epileptiform EEG abnormalities in the absence of clinical seizures.
Study NCT02094651 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is an inactive substance that looks like the active drug.
Study NCT03036020 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CereTom Neurologica Samsung
Description: Diagnosis of acute stroke patients by cerebral CT diagnostics prehospital
Study NCT00933998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metanx® (Oral L-methylfolate, Methylcobalamin and Pyridoxal 5'-phosphate)
Description: One pill twice a day for 2 weeks. Then one pill a day until 12 month study is up.
Study NCT04187495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAX-40279-01
Description: Part 1: Dose escalation, MAX-40279-01 twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1.~For each dose level, a single dose of MAX-40279-01 will be first administered orally followed by 1 day observation, then continuous treatment will start 4 weeks treatment (per cycle).
Study NCT00271102 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anterior vaginal repair (colporrhaphy)
Description: vaginal repair
Study NCT00271102 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: abdominal paravaginal defect repair
Description: abdominal repair
Study NCT04106310 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Theranova dialyzer
Description: a middle cut-off dialyzer
Study NCT02212821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Study NCT02212821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: physiological saline
Study NCT02563028 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SightSaver Visual Stimulator
Description: Evoked response photic stimulator
Study NCT03669445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: 21-day cycles induction and 28-day cycles consolidation
Study NCT03669445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 21-day cycles induction and 28-day cycles consolidation and 28-day cycles maintenance therapy
Study NCT03669445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 21-day cycles induction and 28-day cycles consolidation
Study NCT03669445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: 21-day cycles induction and 28-day cycles consolidation
Study NCT03437122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)
Study NCT04489706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide for injection
Description: Arsenic trioxide for injection, 0.16 mg/kg (maximum single dose is 10 mg), daily IV drip, d1 to d14, once every 28 days, for six cycles of treatment or until one of the following events occurs: Initiation of new anti-tumor therapy, disease progression, withdrawal of Informed consent form (ICF) and/or death.
Study NCT04217941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Health Education and practical demonstration of Nasal spray and intranasal ointment
Description: We compared the effect of Health education and practical demonstration for using nasal spray and apply intranasal ointment compared to health education without practical demonstration
Study NCT01147185 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Locomotor training using a robotic device
Description: 50min walking time, 3-5 trainings/week.
Study NCT01147185 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Locomotor training using a robotic device
Description: 25min walking time, 3-5 trainings/week.
Study NCT04338464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial therapy for South Asian women experiencing mood disorders
Description: The 12 week intervention has four major components:~* Relational theory (Belgrave, 2002) \& South Asian identity development (Inman et al., 2001). These foundational components focus on strengthening cultural identity through the exploration of values, navigation and reconciliation of two cultures.~* Transdiagnostic treatment of mood disorders (Ehrenreich-May et al., 2017). This component will focus on skill building in the areas of emotion awareness, resilience, adaptability, self-compassion and healthy coping strategies (Farchione et al., 2012; Bilek \& Ehrenriech-May, 2012; Ritschel, Noriel \& Lindsay, 2015).~* Psychoeducation on mental health, sexual health, and substance use.~* Peer support is a critical component of the intervention and will be provided by the peer researcher on the team. Participants will have access to optional individual peer support for 30 minutes to one hour per week for the duration of the intervention, this can be in person or telephone support.
Study NCT04939285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP
Description: The patients who met the withdrawal screening criteria were randomly divided into low pressure support level PSV spontaneous respiration test.The duration of the spontaneous breathing test was 30 minutes, and the results of the spontaneous breathing test were evaluated at the end of the test.
Study NCT00006095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT00006095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT05685446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice water
Description: Ingestion of 175 ml iced tap water 15 minutes prior to elective gastroscopy
Study NCT00645606 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: rituximab :500 mg/m² every 8 weeks during 2 years
Study NCT00229931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide
Description: 4mg of intravitreal triamcinolone at time of cataract surgery with option to repeat at one month if no response
Study NCT00229931 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser
Description: Laser treatment 1 month after cataract surgery with option to repeat once if no improvement.
Study NCT01387061 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatic resection
Description: surgical resection of the liver for multiple HCC
Study NCT01858402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 15 mg/kg IV (premixed with 0.9% sodium chloride to a total of 50 ml), preoperative single dose
Study NCT01858402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyrone
Description: 15 mg/kg IV (premixed with 0.9% sodium chloride to a total of 50 ml), preoperative single dose
Study NCT01411124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin enacarbil
Description: 600 mg investigational compound
Study NCT01411124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diphenhydramine
Description: 50 mg active comparator
Study NCT01411124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo
Study NCT01411124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01411124 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT04370808 — intervention group
Intervention type: OTHER
Intervention: Exposure
Description: Individuals with SARS-CoV-2 exposure and COVID-19 symptoms.
Study NCT02226718 — intervention group
Intervention type: OTHER
Intervention: Administration of questionnaire